Literature DB >> 25091968

Alternative therapy for medically refractory angina: enhanced external counterpulsation and transmyocardial laser revascularization.

Ozlem Soran1.   

Abstract

Medically refractory angina pectoris (RAP) is defined by presence of severe angina with objective evidence of ischemia and failure to relieve symptoms with coronary revascularization. Medication and invasive revascularization are the most common approaches for treating coronary artery disease (CAD). Although symptoms are eliminated or alleviated by these invasive approaches, the disease and its causes are present after treatment. New treatment approaches are needed to prevent the disease from progressing and symptoms from recurring. External enhanced counterpulsation therapy provides a treatment modality in the management of CAD and can complement invasive revascularization procedures. Data support that it should be considered a first-line treatment of RAP.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Coronary artery disease; Enhanced external counterpulsation therapy; Medically refractory angina; Transmyocardial laser revascularization

Mesh:

Year:  2014        PMID: 25091968     DOI: 10.1016/j.ccl.2014.04.009

Source DB:  PubMed          Journal:  Cardiol Clin        ISSN: 0733-8651            Impact factor:   2.213


  3 in total

1.  A Novel Intra-aortic Device Designed for Coronary Blood Flow Amplification in Unrevascularizable Patients.

Authors:  Udi Nussinovitch; Giorgi Shtenberg; Ariel Roguin; Yair Feld
Journal:  J Cardiovasc Transl Res       Date:  2016-06-03       Impact factor: 4.132

2.  Predictors of treatment benefits after enhanced external counterpulsation in patients with refractory angina pectoris.

Authors:  Eline Wu; Jan Mårtensson; Liyew Desta; Anders Broström
Journal:  Clin Cardiol       Date:  2021-01-05       Impact factor: 2.882

Review 3.  Does Enhanced External Counterpulsation (EECP) Significantly Affect Myocardial Perfusion?: A Systematic Review & Meta-Analysis.

Authors:  Xiaoxia Qin; Yanye Deng; Dandong Wu; Lehua Yu; Rongzhong Huang
Journal:  PLoS One       Date:  2016-04-05       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.